CO2019005466A2 - Crenolanib to treat mutations associated with proliferative disorders with mutated flt3 - Google Patents
Crenolanib to treat mutations associated with proliferative disorders with mutated flt3Info
- Publication number
- CO2019005466A2 CO2019005466A2 CONC2019/0005466A CO2019005466A CO2019005466A2 CO 2019005466 A2 CO2019005466 A2 CO 2019005466A2 CO 2019005466 A CO2019005466 A CO 2019005466A CO 2019005466 A2 CO2019005466 A2 CO 2019005466A2
- Authority
- CO
- Colombia
- Prior art keywords
- crenolanib
- patient
- mutated
- treat
- mutated flt3
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención incluye métodos para tratar un trastorno proliferativo con FLT3 mutado que comprende: medir la expresión de un FLT3 mutado y una o más anormalidades genéticas en una muestra obtenida de una muestra del tumor obtenida del paciente, en donde la presencia de la una o más anormalidades genéticas indica que el paciente tiene un mal pronóstico; y administrar al paciente una cantidad terapéuticamente efectiva de crenolanib o una de sus sales farmacéuticamente aceptables, en donde el crenolanib aumenta una probabilidad de supervivencia del paciente que tiene el FTL3 mutado y la una o más anormalidades genéticas, en donde el crenolanib, como se muestra a continuación, se administra a un sujeto que sufre de dicho trastorno.The present invention includes methods for treating a proliferative disorder with mutated FLT3 comprising: measuring the expression of a mutated FLT3 and one or more genetic abnormalities in a sample obtained from a sample of the tumor obtained from the patient, wherein the presence of the one or more genetic abnormalities indicates that the patient has a poor prognosis; and administering to the patient a therapeutically effective amount of crenolanib or one of its pharmaceutically acceptable salts, wherein crenolanib increases a survival probability of the patient having the mutated FTL3 and the one or more genetic abnormalities, where crenolanib, as shown then, it is administered to a subject suffering from said disorder.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662416475P | 2016-11-02 | 2016-11-02 | |
US15/799,684 US11078541B2 (en) | 2016-11-02 | 2017-10-31 | Crenolanib for treating FLT3 mutated proliferative disorders associated mutations |
PCT/US2017/059377 WO2018085292A1 (en) | 2016-11-02 | 2017-10-31 | Crenolanib for treating flt3 mutated proliferative disorders associated mutations |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2019005466A2 true CO2019005466A2 (en) | 2019-07-31 |
Family
ID=62020370
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2019/0005466A CO2019005466A2 (en) | 2016-11-02 | 2019-05-24 | Crenolanib to treat mutations associated with proliferative disorders with mutated flt3 |
Country Status (19)
Country | Link |
---|---|
US (2) | US11078541B2 (en) |
EP (1) | EP3359155A4 (en) |
JP (2) | JP2019532011A (en) |
KR (2) | KR20200079351A (en) |
CN (1) | CN108778276A (en) |
AU (1) | AU2017353925A1 (en) |
BR (1) | BR112019008762A2 (en) |
CA (1) | CA3024012A1 (en) |
CL (1) | CL2019001208A1 (en) |
CO (1) | CO2019005466A2 (en) |
EA (1) | EA201991078A1 (en) |
HK (1) | HK1257195A1 (en) |
IL (1) | IL266303A (en) |
MX (1) | MX2019005008A (en) |
PE (1) | PE20191238A1 (en) |
PH (1) | PH12019500965A1 (en) |
SG (1) | SG11201903889TA (en) |
WO (1) | WO2018085292A1 (en) |
ZA (1) | ZA201903089B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019532011A (en) * | 2016-11-02 | 2019-11-07 | アログ・ファーマシューティカルズ・インコーポレイテッドArog Pharmaceuticals,Inc. | Clenolanib for treating FLT3 mutation proliferative disease and related mutations |
US11944627B2 (en) | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
EP3856173A4 (en) * | 2018-09-26 | 2022-07-06 | Kura Oncology, Inc. | Treatment of hematological malignancies with inhibitors of menin |
CN109678849A (en) * | 2019-01-16 | 2019-04-26 | 北京悦康科创医药科技股份有限公司 | A kind of preparation method of anticancer drug |
US11471451B2 (en) | 2019-08-19 | 2022-10-18 | Arog Pharmaceuticals, Inc. | Uses of crenolanib |
CN110531016B (en) * | 2019-09-05 | 2021-08-31 | 合肥诺明药物安全研究有限公司 | HYML-122 blood concentration quantitative analysis method |
US11713310B2 (en) | 2020-07-20 | 2023-08-01 | Arog Pharmaceuticals, Inc. | Crystal forms of crenolanib and methods of use thereof |
US11524006B2 (en) * | 2020-09-17 | 2022-12-13 | Arog Pharmaceuticals, Inc. | Crenolanib for treating TRK kinase associated proliferative disorders |
CN112921091B (en) * | 2021-03-16 | 2022-01-21 | 南京先声医学检验实验室有限公司 | Use of FLT3 gene mutation in predicting sensitivity of non-small cell lung cancer patient to immune checkpoint inhibitor therapy |
JP2023063189A (en) | 2021-10-22 | 2023-05-09 | アログ・ファーマシューティカルズ・インコーポレイテッド | Crenolanib for treating flt3 mutated proliferative disorders relapsing after or refractory to prior treatment |
CN115141886B (en) * | 2022-06-28 | 2023-06-06 | 厦门艾德生物医药科技股份有限公司 | Probe primer set for detecting myelogenous leukemia gene mutation based on high-throughput sequencing and application thereof |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5990146A (en) | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
AU744939B2 (en) | 1997-09-26 | 2002-03-07 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
UA75055C2 (en) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Benzoimidazole derivatives being used as antiproliferative agent, pharmaceutical composition based thereon |
US6656942B2 (en) | 2000-10-17 | 2003-12-02 | Merck & Co., Inc. | Orally active salts with tyrosine kinase activity |
TWI238824B (en) | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
WO2003024969A1 (en) | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2003024931A1 (en) | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
TWI259081B (en) | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
KR20090087139A (en) | 2001-10-30 | 2009-08-14 | 노파르티스 아게 | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
US6686362B2 (en) | 2001-12-27 | 2004-02-03 | Theravance, Inc. | Indolinone derivatives |
TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
PL375447A1 (en) | 2002-08-14 | 2005-11-28 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
AU2003288899B2 (en) | 2002-08-23 | 2009-09-03 | Novartis Vaccines And Diagnostics, Inc. | Benzimidazole quinolinones and uses thereof |
PA8580301A1 (en) | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | NEW BENZOIMIDAZOL DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS |
EP1566379A4 (en) | 2002-10-29 | 2005-11-09 | Kirin Brewery | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME |
EP1565187A4 (en) | 2002-11-13 | 2010-02-17 | Novartis Vaccines & Diagnostic | Methods of treating cancer and related methods |
AR042052A1 (en) | 2002-11-15 | 2005-06-08 | Vertex Pharma | USEFUL DIAMINOTRIAZOLS AS INHIBITORS OF PROTEINQUINASES |
US7226919B2 (en) | 2002-12-18 | 2007-06-05 | Vertex Pharmaceuticals Inc. | Compositions useful as inhibitors of protein kinases |
KR100787649B1 (en) | 2003-06-24 | 2007-12-21 | 화이자 프로덕츠 인크. | Processes for the preparation of 1-[benzoimidazol-1-ylquinolin-8-yl]piperidin-4-ylamine derivatives |
ES2673603T3 (en) * | 2009-04-06 | 2018-06-25 | Vanda Pharmaceuticals Inc. | Treatment method based on polymorphisms of the KCNQ1 gene |
CA2867375A1 (en) * | 2012-03-12 | 2013-09-19 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia |
KR20140040594A (en) | 2012-09-26 | 2014-04-03 | 아로그 파마슈티칼스, 엘엘씨 | Method of inhibiting mutant c-kit |
BR112015016282A2 (en) | 2013-01-07 | 2017-07-11 | Arog Pharmaceuticals Inc | crenolanib for treatment of mutated flt3 proliferative disorders |
JP2019532011A (en) * | 2016-11-02 | 2019-11-07 | アログ・ファーマシューティカルズ・インコーポレイテッドArog Pharmaceuticals,Inc. | Clenolanib for treating FLT3 mutation proliferative disease and related mutations |
-
2017
- 2017-10-31 JP JP2018506309A patent/JP2019532011A/en active Pending
- 2017-10-31 EA EA201991078A patent/EA201991078A1/en unknown
- 2017-10-31 EP EP17866388.6A patent/EP3359155A4/en active Pending
- 2017-10-31 WO PCT/US2017/059377 patent/WO2018085292A1/en active Application Filing
- 2017-10-31 CA CA3024012A patent/CA3024012A1/en active Pending
- 2017-10-31 MX MX2019005008A patent/MX2019005008A/en unknown
- 2017-10-31 KR KR1020207018302A patent/KR20200079351A/en not_active Application Discontinuation
- 2017-10-31 BR BR112019008762A patent/BR112019008762A2/en not_active Application Discontinuation
- 2017-10-31 AU AU2017353925A patent/AU2017353925A1/en not_active Abandoned
- 2017-10-31 CN CN201780016669.1A patent/CN108778276A/en active Pending
- 2017-10-31 PE PE2019000923A patent/PE20191238A1/en unknown
- 2017-10-31 KR KR1020187016693A patent/KR20180074792A/en not_active Application Discontinuation
- 2017-10-31 SG SG11201903889TA patent/SG11201903889TA/en unknown
- 2017-10-31 US US15/799,684 patent/US11078541B2/en active Active
-
2018
- 2018-12-18 HK HK18116172.6A patent/HK1257195A1/en unknown
-
2019
- 2019-04-29 IL IL266303A patent/IL266303A/en unknown
- 2019-04-30 PH PH12019500965A patent/PH12019500965A1/en unknown
- 2019-05-02 CL CL2019001208A patent/CL2019001208A1/en unknown
- 2019-05-17 ZA ZA2019/03089A patent/ZA201903089B/en unknown
- 2019-05-24 CO CONC2019/0005466A patent/CO2019005466A2/en unknown
-
2021
- 2021-06-23 US US17/355,468 patent/US20210324481A1/en active Pending
-
2022
- 2022-03-02 JP JP2022031616A patent/JP2022071099A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210324481A1 (en) | 2021-10-21 |
PH12019500965A1 (en) | 2019-12-02 |
WO2018085292A1 (en) | 2018-05-11 |
MX2019005008A (en) | 2019-09-10 |
SG11201903889TA (en) | 2019-05-30 |
JP2019532011A (en) | 2019-11-07 |
JP2022071099A (en) | 2022-05-13 |
KR20200079351A (en) | 2020-07-02 |
CA3024012A1 (en) | 2018-05-11 |
CL2019001208A1 (en) | 2019-07-26 |
CN108778276A (en) | 2018-11-09 |
HK1257195A1 (en) | 2019-10-18 |
US11078541B2 (en) | 2021-08-03 |
US20180117031A1 (en) | 2018-05-03 |
EP3359155A4 (en) | 2019-05-22 |
BR112019008762A2 (en) | 2019-07-16 |
IL266303A (en) | 2019-06-30 |
AU2017353925A1 (en) | 2018-09-27 |
PE20191238A1 (en) | 2019-09-11 |
KR20180074792A (en) | 2018-07-03 |
ZA201903089B (en) | 2019-12-18 |
EP3359155A1 (en) | 2018-08-15 |
EA201991078A1 (en) | 2019-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019005466A2 (en) | Crenolanib to treat mutations associated with proliferative disorders with mutated flt3 | |
UY36307A (en) | COMBINED THERAPIES FOR CANCER TREATMENT | |
CL2017003427A1 (en) | Antibodies for cd40 | |
JO3735B1 (en) | Tetrasubstituted alkene compounds and their use | |
CR20140108A (en) | CYCLOPROPANOAMINE COMPOUND | |
CL2015002807A1 (en) | Combination therapy | |
CL2015001923A1 (en) | Use of crenolanib for the treatment of proliferative disorders that has mutated flt3 | |
EA201500334A1 (en) | FGFR3 HYBRID GENE AND DRUGS TARGETED ON IT | |
MY176031A (en) | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor | |
CO2018003224A2 (en) | Modified release amino acid formulations administered orally | |
BR112016023025A2 (en) | trastuzumab-resistant her2 + breast cancer targeting with a her3 targeting nanoparticle | |
MX370953B (en) | USE OF LEVOCETIRIZINE and MONTELUKAST IN THE TREATMENT OF AUTOIMMUNE DISORDERS. | |
CY1123501T1 (en) | USE OF RESLIZUMAB IN THE TREATMENT OF MODERATE TO SEVERE EOSINOPHILIC ASTHMA | |
MA40364A (en) | Combination therapy for treatment of cancer | |
BR112015010039A2 (en) | treatment of cancer with pomalidomide in an individual with renal dysfunction | |
MX2019003235A (en) | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor. | |
EA201891007A1 (en) | AIMING FOR FORMILPEPTID RECEPTOR 2 / LIPOXIN A RECEPTOR (FPR2 / ALX) FOR TREATING HEART DISEASES | |
MX2015011905A (en) | Use of levocetirizine and montelukast in the treatment of vasculitis. | |
EA201691860A1 (en) | PEPTIDE MEDICINE AS A DRY POWDER | |
EA201991175A1 (en) | THE USE OF INTERFERON-LAMBDA IN MEDICINE FOR THE TREATMENT OF FIBROSIS | |
PH12015502266A1 (en) | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers | |
EA201691656A2 (en) | THERAPEUTIC WAYS WITH THE USE OF NORIBOGOGINE AND RELATED COMPOUNDS | |
NI201700066A (en) | LOW DOSE A2A ANTAGONISTS FOR THE TREATMENT OF ADHD AND PARKINSON'S DISEASE | |
MX2020006075A (en) | Bendamustine pharmaceutical compositions. | |
EA202091743A1 (en) | DENDRITIC CELL VACCINATION PARALLEL WITH CHEMOTHERAPY |